Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Impact of secondary care financial incentives on the quality of physical healthcare for people with psychosis: a longitudinal controlled study.

Crawford MJ, Huddart D, Craig E, Zalewska K, Quirk A, Shiers D, Strathdee G, Cooper SJ.

Br J Psychiatry. 2019 Jul 5:1-6. doi: 10.1192/bjp.2019.162. [Epub ahead of print]

PMID:
31272513
2.

Exploring a potential mechanistic role of DNA methylation in the relationship between in utero and post-natal environmental exposures and risk of childhood acute lymphoblastic leukaemia.

Timms JA, Relton CL, Sharp GC, Rankin J, Strathdee G, McKay JA.

Int J Cancer. 2019 Dec 1;145(11):2933-2943. doi: 10.1002/ijc.32203. Epub 2019 Mar 19.

PMID:
30740682
3.

Unleashing talent in mental health sciences: gender equality at the top.

Breedvelt JJF, Rowe S, Bowden-Jones H, Shridhar S, Lovett K, Bockting C, Lingford-Hughes A, Strathdee G, Tracy DK.

Br J Psychiatry. 2018 Dec;213(6):679-681. doi: 10.1192/bjp.2018.249.

4.

Maternal Red Blood Cell Folate and Infant Vitamin B12 Status Influence Methylation of Genes Associated with Childhood Acute Lymphoblastic Leukemia.

Potter C, Moorman AV, Relton CL, Ford D, Mathers JC, Strathdee G, McKay JA.

Mol Nutr Food Res. 2018 Nov;62(22):e1800411. doi: 10.1002/mnfr.201800411. Epub 2018 Oct 11.

PMID:
30192066
5.

Carrots and Sticks on Opposite Sides of the Atlantic: Integration Incentives for People With Serious Mental Illness in England.

Ramanuj PP, Breslau J, Strathdee G, Spaeth-Rublee B, Pincus HA.

Psychiatr Serv. 2017 May 1;68(5):430-432. doi: 10.1176/appi.ps.201600095. Epub 2016 Dec 15.

PMID:
27974005
6.

DNA methylation as a potential mediator of environmental risks in the development of childhood acute lymphoblastic leukemia.

Timms JA, Relton CL, Rankin J, Strathdee G, McKay JA.

Epigenomics. 2016 Apr;8(4):519-36. doi: 10.2217/epi-2015-0011. Epub 2016 Apr 1. Review.

7.

Early life trauma, depression and the glucocorticoid receptor gene--an epigenetic perspective.

Smart C, Strathdee G, Watson S, Murgatroyd C, McAllister-Williams RH.

Psychol Med. 2015 Dec;45(16):3393-410. doi: 10.1017/S0033291715001555. Epub 2015 Sep 21. Review.

PMID:
26387521
8.

Epigenetic landscape correlates with genetic subtype but does not predict outcome in childhood acute lymphoblastic leukemia.

Gabriel AS, Lafta FM, Schwalbe EC, Nakjang S, Cockell SJ, Iliasova A, Enshaei A, Schwab C, Rand V, Clifford SC, Kinsey SE, Mitchell CD, Vora A, Harrison CJ, Moorman AV, Strathdee G.

Epigenetics. 2015;10(8):717-26. doi: 10.1080/15592294.2015.1061174.

9.

Aberrations in DNA methylation are detectable during remission of acute lymphoblastic leukemia and predict patient outcome.

van Otterdijk SD, Norden J, Dickinson AM, Pearce MS, Relton CL, Mathers JC, Strathdee G.

Epigenomics. 2015;7(1):35-45. doi: 10.2217/epi.14.78.

PMID:
25687464
10.

Commissioning. London CCGs map out the future of mental health care.

Radford S, Moore A, Fonagy P, Ilves P, Strathdee G, Monks G.

Health Serv J. 2014 Jul 18;124(6407):20-1. No abstract available.

PMID:
25233681
11.

DNA methylation abnormalities at gene promoters are extensive and variable in the elderly and phenocopy cancer cells.

Gautrey HE, van Otterdijk SD, Cordell HJ; Newcastle 85+ Study Core Team, Mathers JC, Strathdee G.

FASEB J. 2014 Jul;28(7):3261-72. doi: 10.1096/fj.13-246173. Epub 2014 May 22.

PMID:
24858281
12.

Acquisition of aberrant DNA methylation is associated with frailty in the very old: findings from the Newcastle 85+ Study.

Collerton J, Gautrey HE, van Otterdijk SD, Davies K, Martin-Ruiz C, von Zglinicki T, Kirkwood TB, Jagger C, Mathers JC, Strathdee G.

Biogerontology. 2014 Aug;15(4):317-28. doi: 10.1007/s10522-014-9500-9. Epub 2014 Apr 26.

PMID:
24770842
13.

Do age-related changes in DNA methylation play a role in the development of age-related diseases?

van Otterdijk SD, Mathers JC, Strathdee G.

Biochem Soc Trans. 2013 Jun;41(3):803-7. doi: 10.1042/BST20120358. Review.

PMID:
23697941
14.

Heterozygote FANCD2 mutations associated with childhood T Cell ALL and testicular seminoma.

Smetsers S, Muter J, Bristow C, Patel L, Chandler K, Bonney D, Wynn RF, Whetton AD, Will AM, Rockx D, Joenje H, Strathdee G, Shanks J, Klopocki E, Gille JJ, Dorsman J, Meyer S.

Fam Cancer. 2012 Dec;11(4):661-5. doi: 10.1007/s10689-012-9553-3.

PMID:
22829014
15.

BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia.

Roy S, Jørgensen HG, Roy P, Abed El Baky M, Melo JV, Strathdee G, Holyoake TL, Bartholomew C.

Br J Haematol. 2012 May;157(4):446-56. doi: 10.1111/j.1365-2141.2012.09078.x. Epub 2012 Feb 29.

PMID:
22372463
16.

Methylation markers in the clinical management of leukemia patients: wave of the future or just damp squib?

Strathdee G.

Epigenomics. 2011 Aug;3(4):391-4. doi: 10.2217/epi.11.63. No abstract available.

PMID:
22126198
17.

Epigenetic inactivation of TWIST2 in acute lymphoblastic leukemia modulates proliferation, cell survival and chemosensitivity.

Thathia SH, Ferguson S, Gautrey HE, van Otterdijk SD, Hili M, Rand V, Moorman AV, Meyer S, Brown R, Strathdee G.

Haematologica. 2012 Mar;97(3):371-8. doi: 10.3324/haematol.2011.049593. Epub 2011 Nov 4.

18.

The dual role of HLXB9 in leukemia.

Ferguson S, Gautrey HE, Strathdee G.

Pediatr Blood Cancer. 2011 Mar;56(3):349-52. doi: 10.1002/pbc.22679.

PMID:
21069786
19.

Methylation markers identify high risk patients in IGHV mutated chronic lymphocytic leukemia.

Irving L, Mainou-Fowler T, Parker A, Ibbotson RE, Oscier DG, Strathdee G.

Epigenetics. 2011 Mar;6(3):300-6. Epub 2011 Mar 1.

20.

Induction of epigenetic alterations by dietary and other environmental factors.

Mathers JC, Strathdee G, Relton CL.

Adv Genet. 2010;71:3-39. doi: 10.1016/B978-0-12-380864-6.00001-8. Review.

PMID:
20933124
21.

DNA methylation does not regulate JUNB expression in CML: comment on "Downregulation of JUNB mRNA expression in advanced phase chronic myelogenous leukemia" by Hoshino et al. [Leuk. Res. 33 (2009) 1361-1366].

Strathdee G, Ferguson S, Sim A, Brown R.

Leuk Res. 2010 May;34(5):685-6. doi: 10.1016/j.leukres.2009.11.016. Epub 2009 Dec 16. No abstract available.

PMID:
20006998
22.

Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors.

Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, Lee C, Barrett S, Reade S, Jadayel D, Tang A, Bellenger K, Mackay L, Setanoians A, Schätzlein A, Twelves C, Kaye SB, Brown R.

J Clin Oncol. 2007 Oct 10;25(29):4603-9.

PMID:
17925555
23.

Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis.

Strathdee G, Holyoake TL, Sim A, Parker A, Oscier DG, Melo JV, Meyer S, Eden T, Dickinson AM, Mountford JC, Jorgensen HG, Soutar R, Brown R.

Clin Cancer Res. 2007 Sep 1;13(17):5048-55.

24.

GATA1 mutational analysis in chronic myeloid leukaemia.

Halsey C, Fisher C, Strathdee G, Gibson B, Holyoake T, Vyas P, Graham G.

Br J Haematol. 2007 May;137(4):375-6. Epub 2007 Apr 4. No abstract available.

PMID:
17408401
25.

Epigenetic markers and response to chemotherapy in cancer.

Strathdee G.

Dis Markers. 2007;23(1-2):43-9. Review.

26.

Screening for cognitive functioning in psychiatric outpatients with schizophrenia, alcohol dependence, and dual diagnosis.

Manning V, Wanigaratne S, Best D, Strathdee G, Schrover I, Gossop M.

Schizophr Res. 2007 Mar;91(1-3):151-8. Epub 2007 Feb 14.

PMID:
17300919
27.

HOXA5 is targeted by cell-type-specific CpG island methylation in normal cells and during the development of acute myeloid leukaemia.

Strathdee G, Sim A, Soutar R, Holyoake TL, Brown R.

Carcinogenesis. 2007 Feb;28(2):299-309. Epub 2006 Jul 21.

PMID:
16861263
28.
29.

Promoter hypermethylation silences expression of the HoxA4 gene and correlates with IgVh mutational status in CLL.

Strathdee G, Sim A, Parker A, Oscier D, Brown R.

Leukemia. 2006 Jul;20(7):1326-9. Epub 2006 May 11. No abstract available.

PMID:
16688227
30.

CpG island methylation of DNA damage response genes in advanced ovarian cancer.

Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, Siddiqui N, Gabra H, McLeod HL, Strathdee G, Brown R.

Cancer Res. 2005 Oct 1;65(19):8961-7.

31.

Epigenetic inactivation of MCJ (DNAJD1) in malignant paediatric brain tumours.

Lindsey JC, Lusher ME, Strathdee G, Brown R, Gilbertson RJ, Bailey S, Ellison DW, Clifford SC.

Int J Cancer. 2006 Jan 15;118(2):346-52.

32.

Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy.

Strathdee G, Vass JK, Oien KA, Siddiqui N, Curto-Garcia J, Brown R.

Gynecol Oncol. 2005 Jun;97(3):898-903.

PMID:
15894365
33.

Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker.

Teodoridis JM, Strathdee G, Brown R.

Drug Resist Updat. 2004 Aug-Oct;7(4-5):267-78. Review.

PMID:
15533764
34.

CpG-island methylation and epigenetic control of resistance to chemotherapy.

Teodoridis JM, Strathdee G, Plumb JA, Brown R.

Biochem Soc Trans. 2004 Dec;32(Pt 6):916-7. Review.

PMID:
15506923
35.

Control of gene expression by CpG island methylation in normal cells.

Strathdee G, Sim A, Brown R.

Biochem Soc Trans. 2004 Dec;32(Pt 6):913-5. Review.

PMID:
15506922
36.

Bioscience 2004.

Strathdee G, Brown R.

Pharmacogenomics. 2004 Oct;5(7):775-8. No abstract available.

PMID:
15469402
37.

Drug deaths in police custody: is dual diagnosis a significant factor?

Best D, Havis S, Strathdee G, Keaney F, Manning V, Strang J.

J Clin Forensic Med. 2004 Aug;11(4):173-82.

PMID:
15363749
38.

Aberrant DNA methylation in cancer: potential clinical interventions.

Strathdee G, Brown R.

Expert Rev Mol Med. 2002 Mar 4;4(4):1-17. doi: 10.1017/S1462399402004222. Review.

PMID:
14987388
39.

Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene.

Strathdee G, Davies BR, Vass JK, Siddiqui N, Brown R.

Carcinogenesis. 2004 May;25(5):693-701. Epub 2004 Jan 16.

PMID:
14729589
40.

Threshold 2: the reliability, validity and sensitivity to change of the Threshold Assessment Grid (TAG).

Slade M, Cahill S, Kelsey W, Powell R, Strathdee G.

Acta Psychiatr Scand. 2002 Dec;106(6):453-60.

PMID:
12392489
41.

Epigenetic versus genetic alterations in the inactivation of E-cadherin.

Strathdee G.

Semin Cancer Biol. 2002 Oct;12(5):373-9. Review.

PMID:
12191636
42.

Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers.

Wei SH, Chen CM, Strathdee G, Harnsomburana J, Shyu CR, Rahmatpanah F, Shi H, Ng SW, Yan PS, Nephew KP, Brown R, Huang TH.

Clin Cancer Res. 2002 Jul;8(7):2246-52.

43.

Epigenetic cancer therapies: DNA methyltransferase inhibitors.

Strathdee G, Brown R.

Expert Opin Investig Drugs. 2002 Jun;11(6):747-54. Review.

PMID:
12036419
44.

Epigenomics and epigenetic therapy of cancer.

Brown R, Strathdee G.

Trends Mol Med. 2002;8(4 Suppl):S43-8. Review.

PMID:
11927287
45.

Threshold 3: the feasibility of the Threshold Assessment Grid (TAG) for routine assessment of the severity of mental health problems.

Slade M, Cahill S, Kelsey W, Powell R, Strathdee G, Valiakalayil A.

Soc Psychiatry Psychiatr Epidemiol. 2001 Oct;36(10):516-21.

PMID:
11768850
46.

A role for mismatch repair in control of DNA ploidy following DNA damage.

Strathdee G, Sansom OJ, Sim A, Clarke AR, Brown R.

Oncogene. 2001 Apr 5;20(15):1923-7.

47.

Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes.

Strathdee G, Appleton K, Illand M, Millan DW, Sargent J, Paul J, Brown R.

Am J Pathol. 2001 Mar;158(3):1121-7.

48.

Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.

Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R.

Cancer Res. 2000 Nov 1;60(21):6039-44.

49.

The integration of mental health care with primary care.

Jenkins R, Strathdee G.

Int J Law Psychiatry. 2000 May-Aug;23(3-4):277-91. No abstract available.

PMID:
10981272
50.

Threshold Assessment Grid (TAG): the development of a valid and brief scale to assess the severity of mental illness.

Slade M, Powell R, Rosen A, Strathdee G.

Soc Psychiatry Psychiatr Epidemiol. 2000 Feb;35(2):78-85.

PMID:
10784370

Supplemental Content

Loading ...
Support Center